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PERSPECTIVES

COVID-19 Vaccine Acceptance: We Need to Start Now
Krutika Kuppalli,1, David M. Brett-Major,2 and Tara C. Smith3

In this perspective, we discuss the importance of developing a vaccine to help curb transmission of severe acute respiratory syndrome coronavirus 2. The question remains: Once a safe and effective vaccine is developed, will the public be willing to get it? We
present information from one of the first tracking polls to assess public attitudes and perceptions toward a possible coronavirus disease 2019 vaccine that suggests public hesitancy over a potential vaccine, concern regarding accelerating clinical trials, and unease
over the vaccine approval process. Public health experts, government officials, advocates, and others in the scientific community
should respect the signals of hesitancy and communicate sensitivity, applying lessons not only to how we message, but also in how
we build this urgently needed vaccine if we are to have successful uptake once available.
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Vaccines as a way to prevent infectious
diseases such as polio, measles, tetanus, and pertussis have been one of the
greatest scientific breakthroughs of the
20th century, leading to decreased morbidity, mortality, and outbreaks [1]. In
a twist of irony, vaccines have become a
victim of their own success in the United
States because most individuals born
in the 1970s and later have not experienced the devastation caused by vaccinepreventable diseases. Additionally, the
antivaccine movement has gained momentum over the past 50 years despite
debunked narratives such as the documentary DTP: Vaccination Roulette
and Andrew Wakefield’s publication in
1998 suggesting the measles, mumps,
and rubella vaccine causes autism [1].
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Additionally, antivaccine celebrity commentary and social media have contributed to the spreading of misinformation
and vaccine hesitancy [1]. Re-emergence
of vaccine-preventable diseases, in particular measles, has become a critical issue
and led the World Health Organization
(WHO) to list vaccine hesitancy as 1 of
the top 10 global health threats in 2019
[2].
In the background of a global community struggling with how to improve
vaccine acceptance, we are now faced
with the eruption and widespread devastation of a pandemic where the global
scientific community is racing to develop
an effective and safe medical countermeasure. The question remains: Once
an effective vaccine is developed, will the
public be willing to get it?
While the pandemic may sway some
previously undecided about vaccines, the
development of the coronavirus vaccine
along with its approval and distribution
over the coming months and years will
affect vaccine acceptance and uptake
when eventually released. Additionally,
this may have downstream consequences
for future health emergencies. In short,
we have a single shot to get this right.
While speed is clearly of the essence,
we must work to ensure that risk communication and social mobilization around
use of a novel vaccine match scientific

evidence and that a skeptical public is
appropriately briefed regarding this important countermeasure. Few in the
public at large—or frankly among health
professionals—understand
systematic
medical product development, let alone
what terms such as “fast-tracked” mean
in practical terms related to the safety
and efficacy of the vaccine product. The
human papillomavirus vaccine was fasttracked, and that fact remains a talking
point for antivaccine groups who have
exploited this same language for arguments against a coronavirus disease 2019
(COVID-19) vaccine [3].
Antivaccine narratives are not the only
danger to a future COVID-19 vaccine.
Social media has increasingly become
a tool for spreading misinformation,
with groups exploiting antivaccine and
antiscience sentiments and promoting
conspiracy theories [4]. Additionally,
concerns over government interference
in the vaccine approval process have
raised public concerns and serve to undermine the rollout of a future COVID19 vaccine [4]. We all should be anchored
in science and prepared to address these
factors along with vaccine hesitancy directly. When we are spending so much
energy and so many resources to develop
a vaccine, it is equally essential that we remain cognizant of the public concerns regarding safety that need to be addressed.
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Table 1.

rollout programs. Alternatively, it could
be because this is the group at greatest
risk of developing adverse events from
COVID-19.
Groups traditionally disenfranchised,
such as those who identified as not being
white or who have lower socioeconomic
status were more likely to be against
speeding up clinical trials for vaccine
development. Finally, when asked if potential benefits of a coronavirus vaccine
would outweigh possible side effects, 54%
of respondents thought that this would
be the case, while 25% remained unsure. Overall, agreement with vaccine use
was strongest among college-educated
adults (66%), while those without college education agreed only 50% of the
time. It should be noted that this poll was
one of the first performed in the United
States during the pandemic, and none of
the authors participated in its design or
conduct.

Despite this poll being conducted during
the early months of the outbreak, public
concerns regarding a COVID-19 vaccine
have persisted and gotten worse as the
pandemic has progressed. A September
survey performed by the Pew Trust of over
10 000 Americans showed that intent to
get a COVID-19 vaccine has declined 72%
from May 2020 across all major political
and demographic groups [6]. This decline
in confidence is attributed to concerns that
one will be approved before its safety and
efficacy are fully understood (77%) and that
the approval process will move too quickly
without establishing appropriate safety and
efficacy (78%) [6]. A December survey, released as vaccination began in health care
workers, showed slight improvement, with
80% of individuals expecting to get the vaccine “eventually.” This moderate increase
may be due to the fall surge in cases, as the
percentage of individuals concerned about
infection was at the highest level since May

Demographics and Characteristics

Total (n = 2200), No. (%)
Gender

The Government Should Accelerate Coronavirus
Vaccine Development, No. (%)
Agree

Disagree

Unknown

Benefits of Coronavirus Vaccine Outweigh
Risk, No. (%)
Agree

Disagree

Unknown

Male

1062 (48)

531 (50)

418 (39)

113 (11)

644 (60)

186 (18)

232 (22)

Female

1138 (52)

390 (35)

610 (53)

139 (12)

556 (49)

260 (23)

322 (28)

Age
18–29 y

457 (21)

160 (35)

247 (54)

50 (11)

257 (57)

109 (23)

92 (20)

30–44 y

555 (25)

221 (39)

266 (48)

70 (13)

291 (52)

115 (21)

149 (27)

45–54 y

330 (15)

127 (39)

167 (50)

36 (11)

161 (49)

74 (22)

96 (29)

55–64 y

421 (19)

173 (41)

188 (45)

59 (14)

212 (50)

82 (20)

127 (30)

65+ y

436 (20)

239 (55)

160 (37)

37 (8)

279 (64)

67 (15)

90 (21)
420 (24)

Ethnicity
White

1722 (78)

761 (45)

779 (44)

182 (11)

974 (57)

327 (19)

Hispanic

349 (16)

115 (33)

192 (55)

42 (12)

190 (54)

81 (24)

78 (22)

African American

274 (12)

91 (33)

144 (53)

39 (14)

120 (44)

73 (26)

81 (30)

Other

204 (9)

68 (34)

106 (51)

31 (15)

106 (52)

45 (22)

52 (26)
186 (22)

Political affiliation
Democrat

861 (39)

368 (43)

427 (49)

66 (8)

491 (58)

184 (20)

Republican

681 (31)

321 (47)

287 (42)

74 (11)

385 (57)

131 (19)

165 (24)

Independent

658 (30)

231 (35)

315 (48)

112 (17)

323 (49)

131 (20)

203 (31)
410 (27)

Education
Less than college

1512 (69)

610 (40)

699 (47)

203 (13)

758 (50)

343 (23)

Bachelor’s degree

444 (20)

196 (44)

220 (49)

29 (7)

282 (64)

71 (16)

90 (20)

Postgraduate education

244 (11)

115 (48)

109 (44)

20 (8)

161 (66)

31 (12)

53 (22)

Income/year
<$50 000

1197 (54)

470 (39)

560 (47)

167 (14)

585 (49)

277 (23)

334 (28)

$50 000–$100 000

653 (30)

283 (43)

315 (49)

55 (8)

388 (60)

123 (18)

143 (22)

>$100 000

350 (16)

168 (48)

153 (44)

29 (8)

227 (65)

47 (13)

77 (22)

Results courtesy the NBC/LX Tracking Poll.
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NBC LX/Morning Consult performed
a tracking poll on March 24 and 25 that
assessed attitudes and perceptions regarding a COVID-19 vaccine among
a random sample of 2200 adults over
18 years of age (Table 1) [5]. The respondents were 48% male and 52% female. Only
30% stated that they would be among the
first to get vaccinated for COVID-19 once
a vaccine is available, and 9% said they
would not. Just under half of respondents did not think that the federal government should accelerate development
of a coronavirus vaccine or skip aspects
of clinical trials. Interestingly, over half of
respondents aged >65 years believed that
the government should consider skipping
clinical trials to accelerate development
of a coronavirus vaccine. Explanations
for this could be that individuals in this
age group have first-hand experiences
with diseases like measles and polio and
remember the effect of successful vaccine

There are also growing data that indicate
that children may be a source of contagion, and long-term morbidity from
SARS-CoV-2 is still being understood.
Given the evolving understanding of coronavirus disease in children, an honest
conversation that includes discussion regarding a broad vaccination campaign for
children will be important.
It is vital that governmental officials
and public health experts understand that
equally important to developing a safe and
efficacious coronavirus vaccine will be
the education, communication, and community engagement to help foster uptake
of this important medical intervention if
we are to stop the COVID-19 pandemic. It
is vital that the scientific community communicate its understanding that the risk of
a poor outcome from anything other than
rigorous product development likely will
reverberate throughout the community
and potentially spill over into fear of other
vaccines, with downstream repercussions
for the management of pervasive threats
and the next emerging disease. Speed is
critical for this urgently needed vaccine,
but ensuring it is safe is our ethical and humanistic responsibility, even if no one in
the public is watching.
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[7]. That there has been such a significant
falloff in public confidence in a COVID-19
vaccine amidst an ongoing pandemic is a
signal that greater attention must be paid
toward communication and messaging
with the public at large.
Factors that are critical when determining vaccine uptake include perceived
safety, efficacy, and disease susceptibility
[1]. Even if the specter of COVID-19
lingers, will that be enough for vaccinehesitant individuals to accept the new
vaccine for their children or themselves? Antivaccine physician Bob Sears
has already suggested that COIVD-19
is “harmless” to anyone but the elderly and vulnerable groups [8], and the
antivaccine group National Vaccine
Information Center (NVIC) suggests that
COVID-19 vaccines may be the first “federal mandatory mass vaccinations” [9].
These groups are sowing fear and suspicion before the vaccines are assessed; as
such, the research behind them needs
to be meticulous and communicated
transparently to the public while trials
are ongoing. Additionally, data thus far
indicate that most children with severe
acute respiratory syndrome coronavirus
2 (SARS-CoV-2) are asymptomatic or
have mild disease, although some may
develop multisystem inflammatory syndrome (MIS-C) after infection, which can
lead to significant cardiac complications.

